Last edition
News about "WuXi Biologics"
WuXi Biologics Receives Brazil GMP Certification for Cancer Therapy Manufacturing
WuXi Biologics has received Brazil ANVISA GMP certification with zero inspection findings, enabling global commercial manufacturing of its innovative cancer immunotherapy.
WuXi Biologics | 02/07/2026 | By News Bureau
WuXi Biologics Secures 4th EMA GMP Certification for Suzhou Facility
WuXi Biologics’ Suzhou Biosafety Testing Center has received its 4th EMA GMP certification, supporting European Union (EU) Marketing Authorisation (MA) applications for 19 biologics from 13 stakeholders.
WuXi Biologics | 18/06/2026 | By News Bureau
WuXi Biologics Completes Topping-Out of Singapore Drug Product Facility
WuXi Biologics has completed the modular topping-out of its Singapore CRDMO hub drug product facility, a key manufacturing site designed to meet stringent standards. Once operational, the facility is expected to produce approximately 100 million pre-filled syringes and vials annually.
WuXi Biologics | 06/06/2026 | By News Bureau | 113
WuXi Biologics Secures South Korea GMP Certification for Key Manufacturing Facilities
The South Korea GMP Certification from the Ministry of Food and Drug Safety strengthens WuXi Biologics’ end-to-end capabilities for commercial production of complex biologics, including cancer therapies.
WuXi Biologics | 23/04/2026 | By News Bureau | 103
Earendil Labs and WuXi Biologics Partner on Bispecific Antibodies and ADCs
Under the agreement, WuXi Biologics will provide end-to-end development and manufacturing services to Earendil Labs, supporting faster regulatory timelines, reliable CMC execution, and scalable global clinical development.
WuXi Biologics | 13/03/2026 | By News Bureau | 134
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
WuXi Biologics | 03/02/2026 | By News Bureau | 219
WuXi Biologics, Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases
WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development of SND006, a novel bispecific antibody targeting inflammatory bowel disease and autoimmune disorders.
WuXi Biologics | 29/01/2026 | By News Bureau | 207
WuXi Biologics Introduces PatroLab to Enable Real-Time, Predictive Biomanufacturing
WuXi Biologics, a global contract research, development and manufacturing organization (CRDMO), has launched PatroLab, a next-generation digital twin platform aimed at reshaping bioprocess development and biologics manufacturing.
WuXi Biologics | 14/01/2026 | By Darshana | 489
WuXi Biologics' Wuxi Facilities Receive MHRA GMP Approval for Ophthalmic Biologic Manufacturing
The UK regulator has certified WuXi Biologics’ DP5 and DPPC sites in Wuxi for commercial production, reinforcing the company’s global GMP-compliant manufacturing capabilities.
WuXi Biologics | 13/01/2026 | By News Bureau | 243
WuXi Biologics, a global contract research, development and manufacturing organisation (CRDMO), has achieved ISO 20400 Sustainable Procurement certification, a globally recognised standard that embeds sustainability principles into procurement practices and promotes transparency, accountability and responsible supply chain management.
WuXi Biologics | 06/01/2026 | By Darshana | 174
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy